AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9540780 — intervention group
Group type: COMPARATOR
Intervention: Elastic TED stockings (Control group)
Number of subjects: 177
Study 8112905 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-depression in ECG at rest
Number of subjects: 190
Study 8112905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ST-depression and low maximal work load
Number of subjects: 190
Study 8112905 — intervention group
Group type: COMPARATOR
Intervention: More sophisticated methods of evaluating the ECG reaction during exercise
Number of subjects: 190
Study 3036936 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha‐2 interferon
Number of subjects: 383
Study 3036936 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 383
Study 3036936 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon
Number of subjects: 383
Study 3036936 — intervention group
Group type: EXPERIMENTAL
Intervention: adriamycin
Number of subjects: 383
Study 29481395 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 14
Study 29481395 — intervention group
Group type: COMPARATOR
Intervention: Control (no botulinum toxin type A)
Number of subjects: 14
Study 27089927 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-exercise intervention (12 months, prescribed in 10 visits from a physiotherapist)
Number of subjects: 340
Study 27089927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 340
Study 26669766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle assisted pushing (GAP) in the upright posture
Number of subjects: 1145
Study 26669766 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture only
Number of subjects: 1145
Study 26669766 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (recumbent/supine posture)
Number of subjects: 1145
Study 22300334 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with stress training program
Number of subjects: 14
Study 22300334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 20684894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain physiology education
Number of subjects: 48
Study 20684894 — intervention group
Group type: COMPARATOR
Intervention: Pacing and self-management education
Number of subjects: 48
Study 18331150 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (specific details not provided)
Number of subjects: 0
Study 18331150 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 0
Study 16329131 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention (standard care plus three visits to teach coping skills)
Number of subjects: 354
Study 16329131 — intervention group
Group type: COMPARATOR
Intervention: Standard hospice care plus three supportive visits
Number of subjects: 354
Study 16329131 — intervention group
Group type: COMPARATOR
Intervention: Standard hospice care
Number of subjects: 354
Study 14658256 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin administration
Number of subjects: 65
Study 14658256 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without indomethacin
Number of subjects: 65
Study 10919934 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 76
Study 10919934 — intervention group
Group type: COMPARATOR
Intervention: No Exercise Training (NT)
Number of subjects: 76
Study 8923361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (target dosage, 40 mg/kg/day)
Number of subjects: 200
Study 8923361 — intervention group
Group type: COMPARATOR
Intervention: Auranofin (6‐9 mg/day)
Number of subjects: 200
Study 8923361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (after excluding patients previously treated with i.m. gold)
Number of subjects: 200
Study 8923361 — intervention group
Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 200
Study 8923361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 200
Study 1399378 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg o.m., for 10 days
Number of subjects: 10
Study 1399378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3888030 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sodium fluoride daily
Number of subjects: 95
Study 3888030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 31666897 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect training (Group II)
Number of subjects: 68
Study 31666897 — intervention group
Group type: COMPARATOR
Intervention: Non-participants in Kinect training (Group I)
Number of subjects: 68
Study 30233000 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Crystalloid (Plasmalyte)
Number of subjects: 44
Study 30233000 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 44
Study 27299909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral self-help manual
Number of subjects: 54
Study 27299909 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 54
Study 25523634 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly low-dose methotrexate (MTX) as an add-on therapy
Number of subjects: 0
Study 25523634 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 21990524 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA) in group A (with IVH)
Number of subjects: 293
Study 21990524 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA) in group B (without IVH)
Number of subjects: 293
Study 19820870 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the medial pectoral nerve (MPN)
Number of subjects: 30
Study 19820870 — intervention group
Group type: COMPARATOR
Intervention: Sectioning of the medial pectoral nerve (MPN)
Number of subjects: 30
Study 17454467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (10 ml 2% lidocaine) injected down the drain before removal
Number of subjects: 36
Study 17454467 — intervention group
Group type: COMPARATOR
Intervention: Conventional drain removal (no lidocaine)
Number of subjects: 36
Study 14997327 — intervention group
Group type: EXPERIMENTAL
Intervention: High UVR exposure group
Number of subjects: 201
Study 14997327 — intervention group
Group type: COMPARATOR
Intervention: Skin cancer patients
Number of subjects: 201
Study 14997327 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related increase in LEP(u/l)
Number of subjects: 201
Study 14997327 — intervention group
Group type: EXPERIMENTAL
Intervention: UVR exposure data collection methods
Number of subjects: 201
Study 11361048 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 (oral administration)
Number of subjects: 104
Study 11361048 — intervention group
Group type: EXPERIMENTAL
Intervention: RNH-6270 (intravenous administration)
Number of subjects: 104
Study 11361048 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 (up to 160 mg/day)
Number of subjects: 104
Study 9732337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control aiming at <150/85 mm Hg (using captopril or atenolol)
Number of subjects: 1148
Study 9732337 — intervention group
Group type: COMPARATOR
Intervention: Less tight control aiming at <180/105 mm Hg
Number of subjects: 1148
Study 7803318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (16 sessions over a six-month period)
Number of subjects: 0
Study 7803318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3044092 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 30
Study 3044092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30916626 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile traction therapy with RestoreX device for 30 to 90 minutes per day
Number of subjects: 110
Study 30916626 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 110
Study 28392547 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of toenail chromium (TCL)
Number of subjects: 288
Study 28392547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) group
Number of subjects: 288
Study 28392547 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-DM group
Number of subjects: 288
Study 27079599 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare PRO rebound tonometry
Number of subjects: 30
Study 27079599 — intervention group
Group type: COMPARATOR
Intervention: Tono-Pen XL tonometry
Number of subjects: 30
Study 27079599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 30
Study 25133997 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body resistance exercise intervention (TOTRX)
Number of subjects: 49
Study 25133997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extensor exercise intervention (LEXT)
Number of subjects: 49
Study 25133997 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 49
Study 22237835 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A)
Number of subjects: 100
Study 22237835 — intervention group
Group type: EXPERIMENTAL
Intervention: PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)
Number of subjects: 100
Study 19876729 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cavitating blastocysts
Number of subjects: 576
Study 19876729 — intervention group
Group type: COMPARATOR
Intervention: Deflated expanded blastocysts
Number of subjects: 576
Study 17362049 — intervention group
Group type: COMPARATOR
Intervention: Sipuleucel-T (APC8015)
Number of subjects: 0
Study 17362049 — intervention group
Group type: EXPERIMENTAL
Intervention: Various immunotherapy approaches (including dendritic cell vaccination, whole cell vaccines, and recombinant viral vectors)
Number of subjects: 0
Study 17362049 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (taxane- and platinum-compound-based)
Number of subjects: 0
Study 15894038 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% glycyrrhetinic acid cream (n=9)
Number of subjects: 18
Study 15894038 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (n=9)
Number of subjects: 18
Study 12080401 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype beta‐glucan cereal (8.1 g% beta‐glucan)
Number of subjects: 16
Study 12080401 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐glucan bar (6.5 g% beta‐glucan)
Number of subjects: 16
Study 12080401 — intervention group
Group type: COMPARATOR
Intervention: Commercial oat bran breakfast cereal (4.4 g% beta‐glucan)
Number of subjects: 16
Study 12080401 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 16
Study 9650129 — intervention group
Group type: EXPERIMENTAL
Intervention: Early induction group (induction the following morning after PROM)
Number of subjects: 1385
Study 9650129 — intervention group
Group type: COMPARATOR
Intervention: Late induction group (induction two days later)
Number of subjects: 1385
Study 9650129 — intervention group
Group type: EXPERIMENTAL
Intervention: Short latency group (contractions started within 2 hours after admission)
Number of subjects: 1385
Study 9471593 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2019667 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (600 mg/m2) + Cisplatin (100 mg/m2) administered intraperitoneally
Number of subjects: 6
Study 7078417 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnSO4 (100 mg/day Zn++)
Number of subjects: 50
Study 7078417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30821349 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion at 50-150 μg/kg/min (Group P)
Number of subjects: 60
Study 30821349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine bolus of 1 μg/kg followed by infusion at 0.5-1.0 μg/kg/hr (Group D)
Number of subjects: 60
Study 30821349 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 60
Study 30821349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 60
Study 31487546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard training)
Number of subjects: 1460
Study 31487546 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone (tailored behavioral communication, using smartphone technology)
Number of subjects: 1460
Study 31487546 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based (tailored behavioral communication, using paper-based tools)
Number of subjects: 1460
Study 28893432 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention for six months
Number of subjects: 199
Study 25283723 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with problem representation transfer (nested sets)
Number of subjects: 0
Study 25283723 — intervention group
Group type: COMPARATOR
Intervention: Training with format shift to natural frequencies
Number of subjects: 0
Study 25047499 — intervention group
Group type: EXPERIMENTAL
Intervention: Child school/daycare functioning
Number of subjects: 134
Study 25047499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of hypoglycaemia
Number of subjects: 134
Study 25047499 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes-related quality of life
Number of subjects: 134
Study 23177894 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zn)
Number of subjects: 808
Study 23177894 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and copper supplementation (Zn + Cu)
Number of subjects: 808
Study 23177894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 808
Study 21596680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART (zidovudine, lamivudine, efavirenz) started at study entry
Number of subjects: 253
Study 21596680 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (zidovudine, lamivudine, efavirenz) started 2 months after randomization
Number of subjects: 253
Study 21596680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 253
Study 21596680 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 253
Study 19159002 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-week education intervention including a two-hour training session once a week for five weeks
Number of subjects: 137
Study 16777649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 201
Study 16777649 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 201
Study 15085366 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 906
Study 15085366 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 906
Study 15085366 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus (no DM)
Number of subjects: 906
Study 15085366 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced atherosclerosis
Number of subjects: 906
Study 15085366 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease without peripheral stenosis
Number of subjects: 906
Study 11777176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 2
Study 10204645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stroke diagnoses
Number of subjects: 546
Study 10204645 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying cause of death
Number of subjects: 546
Study 10204645 — intervention group
Group type: EXPERIMENTAL
Intervention: Data review
Number of subjects: 546
Study 10204645 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial supplementation with alphatocopherol or beta-carotene
Number of subjects: 546
Study 7851515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients adapting pinch force levels to different object loads
Number of subjects: 21
Study 7851515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 21
Study 2516523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus-treated group
Number of subjects: 354
Study 2516523 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated group
Number of subjects: 354
Study 826963 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 49
Study 826963 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 49
Study 826963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31026805 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA group during stair descent
Number of subjects: 22
Study 31026805 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA group during stair ascent
Number of subjects: 22
Study 28673215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg pre‐incision, 0.25 mg/kg/hour intraoperatively, 0.1 mg/kg/hour for 24 hours)
Number of subjects: 80
Study 28673215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28673215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 80
Study 28673215 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion and Placebo
Number of subjects: 80
Study 25771141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (GI)
Number of subjects: 30
Study 25771141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (GII)
Number of subjects: 30
Study 25771141 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (GIII, control group)
Number of subjects: 30
Study 25771141 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (GI, GII, GIII)
Number of subjects: 30
Study 23758933 — intervention group
Group type: EXPERIMENTAL
Intervention: Congregation-based Healthy Beginning Initiative (HBI)
Number of subjects: 0
Study 23758933 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based approach
Number of subjects: 0
Study 21584666 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 110 mg/m(2) + Paclitaxel 200 mg/m(2) every 21 days (dose-escalated)
Number of subjects: 101
Study 21584666 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m(2) + Paclitaxel 175 mg/m(2) every 10 days (dose-dense)
Number of subjects: 101
Study 19735402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 19735402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 16980879 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced red blood cell transfusions
Number of subjects: 268
Study 16980879 — intervention group
Group type: COMPARATOR
Intervention: Standard, nonleukoreduced red blood cell transfusions
Number of subjects: 268
Study 12732792 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of premature CHD
Number of subjects: 848
Study 12732792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 848
Study 12732792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 848
Study 12732792 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 848
Study 12732792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 848
Study 12732792 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 848
Study 11062571 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar plaster of Paris splint
Number of subjects: 102
Study 11062571 — intervention group
Group type: COMPARATOR
Intervention: Bulky wool and crepe bandage
Number of subjects: 102
Study 9315572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (ionic low osmolality contrast media)
Number of subjects: 30
Study 9315572 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (nonionic low osmolality contrast media)
Number of subjects: 30
Study 9315572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 30
Study 9315572 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 30
Study 8881548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transillumination-guided intubation (TL)
Number of subjects: 30
Study 8881548 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 30
Study 2567754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal culture method
Number of subjects: 0
Study 2567754 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter tip cultures
Number of subjects: 0
Study 2567754 — intervention group
Group type: COMPARATOR
Intervention: Cultures from the insertion site
Number of subjects: 0
Study 2567754 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intraluminal culture and catheter-tip culture
Number of subjects: 0
Study 2567754 — intervention group
Group type: COMPARATOR
Intervention: Comparison of skin puncture site and catheter-tip culture
Number of subjects: 0
Study 1164334 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbent position
Number of subjects: 100
Study 1164334 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 100
Study 31578176 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent heat eyelid warming device at 45 °C
Number of subjects: 15
Study 31578176 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent heat eyelid warming device at 50 °C
Number of subjects: 15
Study 31578176 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent heat eyelid warming device at 55 °C
Number of subjects: 15
Study 31166706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 80
Study 31166706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26976659 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga in combination with standard treatment
Number of subjects: 80
Study 26976659 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 80